Avadel Pharmaceuticals (AVDL) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Launch progress and financial performance

• Achieved four consecutive quarters of exceeding estimates and is nearing cash flow break-even, supported by over 95% gross margins.

• Rapid transition from pre-approval to launch within four weeks, strengthening the balance sheet through cash generation.

• Market research and execution have positioned the product for potential blockbuster status.

Patient acquisition and market expansion

• Patient growth is driven by three segments: switch patients, naive patients, and previously treated/discontinued oxybate users, totaling up to 50,000 potential patients.

• Over 100 prescribers new to oxybates have begun prescribing, many without direct promotion, indicating strong product value.

• Nearly 20% of enrollments come from physicians not actively targeted, highlighting organic market expansion.

• Market research predicted expansion of prescribers and patients, which is materializing faster than expected.

Market opportunity and competitive positioning

• The addressable market includes 14,000 active twice-nightly patients, 12,000–15,000 previously treated/discontinued, and 3,000–4,000 annual new starts.

• Only 10% of the opportunity is from new starts; 90% is from other segments, providing a unique advantage.

• Market potential is estimated at over $1 billion, with early signs of broader adoption, especially among previously untreated patients.